金吾财讯 | 交银国际表示，据国家医保局公布，截至1月20日，近90%的基本医保目录上新药品和商保目录药品已实现进院和终端覆盖，该机构建议持续关注医保新药放量节奏及商保目录落地进展。1月27日，先声药业的TL1A/IL-23双抗授权许可给勃林格殷格翰，总对价超10亿欧元。该机构认为，2026年板块稳中向好态势延续，但仍有短期波动的可能，选股逻辑或将重回基本面和估值，关注存在基本面预期差、仍被低估、安全边际较大的头部个股。该机构推荐关注以下细分方向：1）创新药：三生制药、和黄医药、百济神州等催化剂丰富、估值仍未反映核心大单品价值，可重点关注大单品的关键海外数据读出时间线；先声药业等标的被明显低估、长期成长逻辑清晰之标的，肿瘤和自免管线仍有诸多BD授权机会；2）CXO：受益于下游高景气度和融资边际回暖的细分赛道龙头，如药明合联；3）监管不确定性逐步缓解、叠加政策利好预期，有反转机会的医院、器械和诊断等子板块。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.